TaqMan real time PCR for the Detection of the Gilbert’s Syndrome Markers UGT1A1*28; UGT1A1*36 and UGT1A1*37

被引:0
作者
Valentina Daprà
Carla Alliaudi
Ilaria Galliano
Maddalena Dini
Giada Lo Curcio
Cristina Calvi
Marialaura Archetti
Martina Gavatorta
Massimiliano Bergallo
机构
[1] University of Turin,Department of Public Health and Pediatrics, School of Medicine
[2] BioMole srl.,undefined
来源
Molecular Biology Reports | 2021年 / 48卷
关键词
Real time PCR; Gilbert's syndrome; Allelic discrimination; UGT1A1*28; UGT1A1*36; UGT1A1*37; Pharmacogenetics;
D O I
暂无
中图分类号
学科分类号
摘要
Gilbert’s syndrome is characterized by mild unconjugated hyperbilirubinemia. The key of this disease is a diminished activity of UDP-glucuronosyltransferase 1A1 (UGT1A1). TA insertion into the TATA box promoter region of the UGT1A1 gene on chromosome 2 is the genetic basis of Gilbert’s syndrome (UGT1A1*28). An extra TA insert leads to eight (TA)8 repeats (UGT1A1*37) resulting in a further reduction of glucuronidation activity. A variant lacking one TA repeat (TA)5 (UGT1A1*36) has been identified. (TA)8 repeats (UGT1A1*37) and (TA)5 (UGT1A1*36) have been detected in Africans (frequency up to 0.07 and 0.08 respectively). We present a real time PCR method for genotyping the UGT1A1 (TA)n polymorphism (UGT1A1*28, UGT1A1*36, UGT1A1*37) using Taqman PCR on 7500 and cfx96 Real-Time PCR System. We present a real time PCR method for genotyping the UGT1A1 (TA)n polymorphism (UGT1A1*28, UGT1A1*36, UGT1A1*37) using Taqman PCR. About clinical validation, all 53 samples collected from patients referred for suspected Gilbert’s syndrome were analyzed. We found 21 on the 53 patients (39.6%) were homozygotes (UGT1A1-TATA (TA)6) and referred as wild-type, 13 on the 53 patients (24.5%) were homozygotes (UGT1A1-TATA (TA)7) and referred as mutated, 1 on the 53 patients (1.9%) were homozygotes (UGT1A1-TATA (TA)8) and referred as mutated, 1 on the 53 patients (1.9%) were heterozygotes (UGT1A1-TATA (TA)7/8) and referred as mutated, 1 on the 53 patients (1.9%) were heterozygotes (UGT1A1-TATA (TA)5/6) and referred as mutated, and 16 on the 53 patients (30.2%) were heterozygotes (UGT1A1-TATA (TA)6/7). None were homozygotes UGT1A1-TATA (TA)5, homozygotes UGT1A1-TATA (TA)8, or heterozygotes with (TA)5 or (TA)8 alleles. The newly described technique represents a valid alternative method to sequencing, mainly due to its rapidity, easiness, and minor costs.
引用
收藏
页码:4953 / 4959
页数:6
相关论文
共 50 条
[41]   Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab [J].
Lee, Janet S. ;
Wang, Jianmei ;
Martin, Mitchell ;
Germer, Soren ;
Kenwright, Andrew ;
Benayed, Ryma ;
Spleiss, Olivia ;
Platt, Adam ;
Pilson, Robert ;
Hemmings, Andrew ;
Weinblatt, Michael E. ;
Kaplowitz, Neil ;
Krasnow, Joel .
PHARMACOGENETICS AND GENOMICS, 2011, 21 (07) :365-374
[42]   Hydrogel microarray for detection of polymorphisms in the UGT1A1, DPYD, GSTP1 and ABCB1 genes [J].
Heydarov, Rustam ;
Titov, Sergei ;
Abramov, Mikhail ;
Timofeev, Edward ;
Mikhailovich, Vladimir .
CANCER BIOMARKERS, 2017, 18 (03) :265-272
[43]   The relationship between UGT1A1 gene & various diseases and prevention strategies [J].
Liu, Dan ;
Yu, Qi ;
Ning, Qing ;
Liu, Zhongqiu ;
Song, Jie .
DRUG METABOLISM REVIEWS, 2022, 54 (01) :1-21
[44]   UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers [J].
Graber, Andrea L. Yoder ;
Ramirez, Jacqueline ;
Innocenti, Federico ;
Ratain, Mark J. .
PHARMACOGENETICS AND GENOMICS, 2007, 17 (08) :619-627
[45]   Homozygous variant of UGT1A1 gene mutation and severe neonatal hyperbilirubinemia [J].
Boo, Nem-Yun ;
Wong, Fei-Liang ;
Wang, May-Kay ;
Othman, Ainoon .
PEDIATRICS INTERNATIONAL, 2009, 51 (04) :488-493
[46]   A clinical PCR fragment analysis assay for TA repeat sizing in the UGT1A1 promoter region [J].
Abou Tayoun, Ahmad N. ;
de Abreu, Francine B. ;
Lefferts, Joel A. ;
Tsongalis, Gregory J. .
CLINICA CHIMICA ACTA, 2013, 422 :1-4
[47]   UGT1A1 Genetic Analysis as a Diagnostic Aid for Individuals with Unconjugated Hyperbilirubinemia [J].
Skierka, Jennifer M. ;
Kotzer, Katrina E. ;
Lagerstedt, Susan A. ;
O'Kane, Dennis J. ;
Baudhuin, Linnea M. .
JOURNAL OF PEDIATRICS, 2013, 162 (06) :1146-U107
[48]   Preparation of reference material for UGT1A1 (TA)n polymorphism genotyping [J].
Mlakar, Vid ;
Mlakar, Simona Jurkovic ;
Marc, Janja ;
Ostanek, Barbara .
CLINICA CHIMICA ACTA, 2014, 435 :24-28
[49]   Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia [J].
Sugatani, J ;
Yamakawa, K ;
Yoshinari, K ;
Machida, T ;
Takagi, H ;
Mori, M ;
Kakizaki, S ;
Sueyoshi, T ;
Negishi, M ;
Miwa, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 292 (02) :492-497
[50]   The clinical application of UGT1A1 pharmacogenetic testing: Gene– environment interactions [J].
Marques S.C. ;
Ikediobi O.N. .
Human Genomics, 4 (4) :238-249